Myriad Genetics, Inc saw a rather consistency, in terms of market performance. The company’s stock reached its highest point at $29.30 on 09/18/24, while the lowest price for the same duration was marked at $15.03 on 11/02/23.
52-week price history of MYGN Stock
A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Myriad Genetics, Inc’s current trading price is -40.78% away from its 52-week high, while its distance from the 52-week low is 15.44%. The stock’s price range during this period has spanned from $15.03 to $29.30. In the Healthcare sector, the Myriad Genetics, Inc’s shares surpassed a trading volume of approximately 2.27 million for the day, which was noticeably higher compared to the average daily volume of 9.0.66 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Myriad Genetics, Inc (MYGN) has experienced a quarterly decline of -32.86% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.58B and boasts a workforce of 2700 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 25.89, with a change in price of -5.09. Similarly, Myriad Genetics, Inc recorded 744,035 in trading volume during the last 100 days, posting a change of -22.65%.
Examining MYGN’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for MYGN stands at 0.19. Similarly, the long-term debt-to-equity ratio is also 0.18.
MYGN Stock Stochastic Average
Today, Myriad Genetics, Inc’s raw stochastic average for the past 50 days stands at 3.95%, indicating a decline from the raw stochastic average of the last 20 days, which was 5.05%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 11.30% and 12.83% respectively.
MYGN Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The index has shown a price loss of -9.35% this year. Over the last six months, there has been a stronger performance of -10.89%. The price of MYGN leaped by -34.35% during the last 30 days period. For the last 5-days stocks have slided -19.53%.
